 I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed with plonmarlimab also known as TJM2 in a Phase 1b study CXSL1900100; NCT04457856 to evaluate its use in treating patients with rheumatoid arthritis RA in China. 